Magnolia Neurosciences Corporation Announces that its Subsidiary Receives $20 Million CPRIT Grant to Develop Novel Therapies to Treat Chemotherapy-Induced Neurological Conditions

NEW YORK, NY and HOUSTON, TX – August 27, 2018 – Magnolia Neurosciences Corporation (Magnolia) today announced that Korysso Therapeutics, Inc. (DBA: Magnolia Tejas Corporation), the company’s wholly owned, Houston-based subsidiary, has been awarded a $19.95 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the development of a novel targeted therapy for the treatment of neurological conditions
caused by chemotherapy. Once the grant contract is consummated, CPRIT will fund the advancement of the company’s lead molecule through the completion of Phase 1 and into Phase 2a clinical development. The company expects to initiate a Phase 1 clinical trial in the second half of 2019.

Magnolia Tejas is developing a targeted therapy for these conditions, including chemotherapyinduced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive dysfunction (CICD or chemo brain) based on discoveries made by scientists in The University of Texas MD Anderson Cancer Center’s (MD Anderson) Therapeutics Discovery division and the Neurodegeneration Consortium (NDC).

CIPN results from drug-induced damage to peripheral nerves, which results in pain, numbness and tingling in the hands and feet. It is estimated that in the United States alone there are two million people living with CIPN and there is no approved therapy for the condition. CICD, which affects more than 200,000 patients each year, is characterized by general cognitive and memory problems that can last for years.

“The neuropathy and neurocognitive challenges caused by chemotherapy not only decrease a patient’s quality of life, but also can prevent them from completing the optimal chemotherapy regimen, ultimately affecting survival,” said Philip Jones, Ph.D., vice president of Therapeutics Discovery at MD Anderson, co-author of the CPRIT grant and a scientific advisor to Magnolia Neurosciences. “New treatments that address the underlying cause of CIPN are urgently needed, and a targeted approach has the potential to address the specific biologic mechanisms that contribute to peripheral nerve damage. We greatly appreciate the support from CPRIT to fund this important project.”

“Focusing on CIPN will provide near-term proof of concept for Magnolia Neurosciences’ targeted approach to neuroprotection,” said Thong Q. Le, chief executive officer at Magnolia Neurosciences Corporation and Accelerator Life Science Partners. “Coming on the heels of our recently announced $31M Series A financing, this grant from CPRIT will accelerate our entry into the clinic to treat patients with these often-crippling consequences of chemotherapy.”

CPRIT provides funding through its academic research, prevention, and product development research programs. Programs made possible with CPRIT funding have reached all 254 counties of the state of Texas, brought more than 159 distinguished researchers to the state, advanced scientific and clinical knowledge, and provided more than four million life-saving education, training, prevention, and early detection services to Texans. To date, CPRIT has awarded $2.15 billion in grants for cancer research.

About Magnolia Neurosciences Corporation
Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company endeavors to make life-changing medicines for the benefit of patients and their families suffering from serious CNS diseases. The company was launched by a $31M Series A investment by Accelerator Life Science Partners in 2018 and was co-founded by world class researchers at The University of Texas MD Anderson Cancer Center. The company’s offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science campus. The company also has a wholly owned subsidiary, Magnolia Tejas Corporation, based in Houston, Texas that is focused on developing a novel therapy for chemotherapy-induced neurological conditions. For more information, please visit www.magnolianeurosciences.com.


Accelerator Life Science Partners Broadens its Leadership Teams and Expands its Geographic Operations to San Diego and the Greater Los Angeles Area

  • Newly formed Operating Partners group and Clinical and Scientific Advisory Board to provide critical insights to support portfolio companies’ success and guide investment strategies
  • Additional facility expected to catalyze the growth of innovative life science companies in Southern California

SEATTLE and NEW YORK – May 15, 2018 — Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has expanded its operations into San Diego and the Greater Los Angeles area with the opening of a new office at The Alexandria at Torrey Pines in San Diego. The firm also announced the formation of its Operating Partners group and Clinical and Scientific Advisory Board (CSAB). These strategic growth initiatives will better enable Accelerator to fulfill its dual missions of providing unique and compelling opportunities to its investors and partnering with cutting-edge life science companies to help achieve their near-term milestones and long-term visions.

“Accelerator is committed to supporting innovation wherever it takes place and without geographic limitation,” said David M. Schubert, chief operating partner at Accelerator. “Opening an office in San Diego, our third market, positions us to meet the needs of leading innovators throughout the vibrant San Diego and emerging Greater Los Angeles life science ecosystems. We have also brought together an experienced group of Operating Partners to support our ongoing efforts to identify new investment areas and specific company-building opportunities.”

Accelerator’s Operating Partners will assist with the evaluation of new business opportunities, support current (and future) Accelerator portfolio companies and serve in a variety of operating and board roles. The Operating Partners include:

  • Andrew Howard, Ph.D. (New York City, NY)
  • Wendy S. Johnson (San Diego, CA)
  • David L. Pompliano, Ph.D. (New York City, NY)
  • Francisco D. Salva (Philadelphia, PA)
  • John T. Santini, Jr., Ph.D. (Minneapolis, MN)
  • David M. Schubert  (New York City, NY)
  • Christopher T oombs, Ph.D. (Seattle, WA)
  • Court R. Turner, J.D. (San Diego, CA)

“Having state-of-the-art laboratories and world-class scientific leadership will help set our portfolio companies on a path to long-term success,” said Kendall Mohler, Ph.D., chief development officer at Accelerator. “We are excited to welcome our CSAB members to the Accelerator team. Advancing a groundbreaking scientific idea into and through clinical development takes not only robust data; it also requires critical insights into preclinical research, clinical trial design and strategy and keen understanding of the product approval pathway. Our CSAB members have demonstrated expertise in these areas, and we believe they will be an important asset as we partner with today’s most cutting-edge entrepreneurs.”

Accelerator’s CSAB Members:

  • Lee E. Babiss, Ph.D.
  • John Latham, Ph.D.
  • George L. McLendon, Ph.D.
  • Kendall M. Mohler, Ph.D.
  • Gerald T. Nepom, M.D., Ph.D.
  • Homer L. Pearce, Ph.D.
  • Anil K. Singhal, Ph.D.
  • James Tobin, Ph.D.

Additional information about the members of Accelerator’s Operating Partners and CSAB is available at: www.acceleratorlsp.com/our-team/.

About Accelerator Life Science Partners
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations. Accelerator is a trusted partner that provides the complete business, scientific and financial toolkit necessary for successfully establishing and operating an early-stage biotechnology company. Accelerator nurtures its companies across all stages and in all facets of development, setting them on a path that offers the greatest chance for long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise and state-of-the-art laboratories and shared facilities.

The company is uniquely positioned to provide this unprecedented collection of capabilities and resources through its partnership with top-tier investors, seasoned executive managers and world-class research institutions. The value of these collective resources has been validated over more than a decade of successful investing in life science companies that are helping to shape the rapidly evolving future of medicine and healthcare. For more information, please visit www.acceleratorlsp.com

 

Media Contacts:

Rathbun Communications
Julie Rathbun
julie@rathbuncomm.com

Accelerator Life Science Partners
Jessica Burback
jburback@acceleratorlsp.com
T: 206-234-6481


Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech

  • Collaboration provides Genentech with access to Lodo Therapeutics’ proprietary metagenomics-based natural products drug discovery platform
  • Lodo to receive up to $969 million in upfront fees and milestone payments

New York, NY – May 9, 2018 – Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.

Under the terms of the agreement, Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech. Lodo will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments up to $969 million based on achievement of certain predetermined milestones. In addition, Lodo is eligible to receive tiered-royalties on sales of certain products resulting from the collaboration.

“Lodo Therapeutics’ proprietary drug discovery platform is a powerful engine for identifying novel compounds with important therapeutic potential,” said Thong Q. Le, chief executive officer at Lodo Therapeutics and Accelerator Life Science Partners. “We are incredibly excited to work with Genentech, and we look forward to demonstrating the power and utility of Lodo’s unique technology for the benefit of global human health.”

Compounds derived from natural products comprise a significant proportion of the small molecule drugs used to treat cancer, infections and chronic illnesses such as Type 2 diabetes. Rather than relying on culturing known strains of bacteria, Lodo Therapeutics’ genome-based approach leverages the power of microbial evolution to identify novel, naturally occurring compounds that have therapeutic potential in the treatment of cancer and drug-resistant bacterial infections. This approach is expected to reduce the time and cost of drug discovery.

“Our ability to enter into a strategic collaboration with one of the leaders in innovating wholly new classes of drugs just two years after Lodo Therapeutics was founded reflects the potential of our proprietary platform to be a valuable resource to advance their drug discovery initiatives,” said David Pompliano, Ph.D., co-founder and chief scientific officer of Lodo Therapeutics.

“We are excited to work with Genentech in their quest to discover novel, next-generation natural products derived from the microbiome of the soil using this innovative platform developed by Lodo,” said Sean Brady, Ph.D., co-founder of Lodo Therapeutics and Associate Professor at The Rockefeller University.

James Sabry, M.D., Ph.D., senior vice president and global head of Genentech Partnering, commented, “Genentech is committed to accessing innovative technologies and we are excited to collaborate with Lodo Therapeutics to apply their Metagenomics Technology Platform to potentially discover therapeutics for difficult drug targets.”

About Lodo Therapeutics
Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of novel therapeutics derived from nature that will impact patients around the world. The company was established to pursue the scientific vision of Dr. Sean Brady, head of The Rockefeller University’s Laboratory of Genetically Encoded Small Molecules. Lodo Therapeutics identifies and produces bioactive natural products directly from the microbial DNA sequence information contained in soil. Information encoded in bacterial genomes, not experimental serendipity, drives the company’s discovery of new medicines. Not constrained by traditional culture-based approaches to natural products drug discovery, Lodo Therapeutics has unlocked a vast trove of overlooked compounds evolutionarily selected for processes essential for life and with significant potential in the treatment of drug-resistant microbial infections and cancers

Lodo Therapeutics was formed by Accelerator Life Science Partners and is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science campus.

 

Media Contact(s)

Rathbun Communications
Julie Rathbun
julie@rathbuncomm.com

Accelerator Life Science Partners
Jessica Burback
jburback@acceleratorlsp.com


Proniras Corporation Awarded Contract Worth Up to $89.5 Million from U.S. Biomedical Advanced Research and Development Authority to Develop Tezampanel as a Medical Countermeasure for Nerve Agent-Induced Seizures

SEATTLE, WA – April 27, 2018 – Proniras Corporation, an Accelerator Life Science Partners (Accelerator) portfolio company, today announced that it has been awarded a contract potentially worth $89.5 million from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) to develop tezampanel as a medical countermeasure for the treatment of nerve agent-induced seizures that are not stopped by current medications. Tezampanel (also known as LY-293,558) is a small molecule compound that previously had been evaluated in clinical trials as a potential therapy for acute migraine and other neurologic indications and has demonstrated an attractive safety and pharmacokinetic profile in more than 400 human subjects.

“As recent events have clearly demonstrated, the need for medical countermeasures that can effectively treat nerve agent exposure is sadly more than theoretical,” said Christopher Toombs, PhD, DABT, chief scientific officer at Proniras. “Tezampanel holds great potential as a solution to this serious challenge, having shown favorable safety and pharmacokinetic profiles in clinical trials for acute migraine and demonstrating efficacy in preclinical models of nerve agent-induced seizures. Proniras is pleased to have the opportunity to work with BARDA to improve our nation’s health and security preparedness.”

Under the terms of the contract, Proniras will be responsible for conducting preclinical studies, and the clinical development and manufacture of tezampanel. Payments totaling up to $89.5 million can be made upon attainment of pre-specified milestones over a five-year period. Given the inability to assess the safety and efficacy of tezampanel in humans with actual nerve agent exposure, tezampanel will be developed using the U.S. Food and Drug Administration’s (FDA) Animal Rule (21 CFR 314.600). Under this rule, the FDA can accept a New Drug Application for tezampanel based on efficacy data from a pivotal study in animal models of nerve agent-induced seizures and Phase 1 and 2 trials in human subjects with other relevant neurologic conditions, and adequate safety data from trials in healthy human volunteers.

Proniras expects to file an Investigational New Drug application with the FDA to initiate human trials as well as an application for an Orphan Drug designation in 2020 and anticipates receiving an NDA in 2022. The company may also evaluate continuing development of tezampanel in additional commercial indications following its approval as a medical countermeasure.

Tezampanel is a competitive, reversible receptor antagonist that inhibits glutamate signaling through the GluK1 receptor subunit. This is a novel mechanism of action that is distinct from currently approved seizure medications. Recent studies demonstrate that tezampanel is effective in arresting seizures in rodents exposed to the nerve agent, soman.1 Organophosphate nerve agents initiate seizures through cholinergic stimulation, and seizure activity can increase and be propagated by increasing glutamate signaling. While benzodiazepines are currently used for treatment of seizures caused by nerve agents, data show that, with time, seizures can become refractory to benzodiazepines, often returning and worsening in severity after a brief period of suppression. The superior efficacy of tezampanel, compared with benzodiazepines, in rodents exposed to soman may result in part from its direction inhibition of glutamate signaling, which plays a causal role in seizure activity.

“The robust body of human safety data and clinical, manufacturing and control data, coupled with the results of studies in a rodent model of nerve agent-induced seizures, is very compelling and should substantially reduce the development timeline, cost and risk of developing tezampanel as a medical countermeasure,” said David M. Schubert, chief operating officer at Proniras Corporation and chief operating partner at Accelerator Life Science Partners. “BARDA has a demonstrated track record of success in establishing public-private partnerships that support effective development of medical countermeasures. In addition to the funding provided under the contract, we expect that BARDA’s insight and expertise in the health preparedness arena will play a key role in the development of tezampanel.”

About Proniras Corporation
Proniras Corporation is a Seattle-based biopharmaceutical company focused on developing tezampanel as a medical countermeasure for nerve agent-induced seizures. The development of tezampanel in this indication is being funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800008C.

About Accelerator Life Science Partners
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations. Accelerator is a trusted partner that provides the complete business, scientific and financial toolkit necessary for successfully establishing and operating an early-stage biotechnology company. Accelerator nurtures its companies across all stages and in all facets of development, setting them on a path that offers the greatest chance for long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise and state-of-the-art laboratories and shared facilities.

The company is uniquely positioned to provide this unprecedented collection of capabilities and resources through its partnership with top-tier investors, seasoned executive managers and world-class research institutions. The value of these collective resources has been validated over more than a decade of successful investing in life science companies that are helping to shape the rapidly evolving future of medicine and healthcare. For more information, please visit www.acceleratorlsp.com.

1 Apland, JP, Aroniadou-Anderjaska, V, Figueiredo, TH, Green, CE, Swezey, R, Yang, C, Qashu, F, and and Braga, MFM. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration. JPET 2013: 344-133-140.

 

Media Contacts:

Rathbun Communications
Julie Rathbun
julie@rathbuncomm.com

Accelerator Life Science Partners
Jessica Burback
jburback@acceleratorlsp.com
T: 206-234-6481


Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders

SEATTLE, WA – April 27, 2018 – Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has launched Proniras Corporation, a company developing tezampanel for the treatment of a variety of seizure disorders. Proniras has licensed exclusive global rights to tezampanel (LY-293,558), a small molecule compound that has been evaluated as a potential therapy for acute migraine in more than 400 patients to date, from Eli Lilly and Company. The launch of Proniras is supported by an initial financing from investors including Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., Watson Fund, L.P., WRF Capital and WuXi AppTec Corporate Ventures.

Recent studies demonstrate that tezampanel effectively arrests seizures in rodents exposed to the nerve agent soman1 and is potentially superior to benzodiazepines, which are the current standard of care for a variety of seizure disorders. Data from previous preclinical studies of tezampanel suggest that the compound elicits its central nervous system effects by antagonizing glutamate signaling.

“Treatment of seizures that result from either physiologic or pharmacologic stimuli is suboptimal for many patients,” said Christopher Toombs, PhD, DABT, co-founder and chief scientific officer at Proniras. “A robust body of clinical and preclinical data supports the potential utility of tezampanel as a novel therapy for seizures and seizure disorders. We believe that tezampanel could address significant unmet need for a safe, effective and durable seizure therapy.”

Dr. Toombs was most recently co-founder and chief scientific officer of Faraday Pharmaceuticals, a Seattle-based biotechnology company. Previously, he held senior leadership positions at Cylerus, Inc., Ikaria, Inc. and Amgen, Inc. Accelerator will manage the company’s executive operations.

“With tezampanel as its lead asset, Proniras is being established with a more advanced product development program than is typical for a start-up biopharmaceutical company,” said Thong Q. Le, chief executive officer at Accelerator. “As a result, we believe that Proniras has substantial near- and mid-term opportunities for value creation in an indication that has not seen significant innovation in many years.”

About Proniras Corporation
Proniras Corporation is a Seattle-based biopharmaceutical company focused on developing tezampanel as a medical countermeasure for nerve agent-induced seizures. The development of tezampanel in this indication is being funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800008C. For more information, please visit www.proniras.com.

About Accelerator Life Science Partners
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations. Accelerator is a trusted partner that provides the complete business, scientific and financial toolkit necessary for successfully establishing and operating an early-stage biotechnology company. Accelerator nurtures its companies across all stages and in all facets of development, setting them on a path that offers the greatest chance for long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise and state-of-the-art laboratories and shared facilities.

The company is uniquely positioned to provide this unprecedented collection of capabilities and resources through its partnership with top-tier investors, seasoned executive managers and world-class research institutions. The value of these collective resources has been validated over more than a decade of successful investing in life science companies that are helping to shape the rapidly evolving future of medicine and healthcare. For more information, please visit www.acceleratorlsp.com.

1 Apland, JP, Aroniadou-Anderjaska, V, Figueiredo, TH, Green, CE, Swezey, R, Yang, C, Qashu, F, and and Braga, MFM. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration. JPET 2013: 344-133-140.

 

Media Contacts:
Rathbun Communications
Julie Rathbun
julie@rathbuncomm.com

Accelerator Life Science Partners
Jessica Burback
jburback@acceleratorlsp.com
T: 206-234-6481


Accelerator Corporation Announces Key Senior Leadership Appointments and Name Change to Accelerator Life Science Partners

  • Biotechnology industry veterans bring decades of experience in working collaboratively to innovate breakthrough life science products

SEATTLE, Wash. and NEW YORK – December 13, 2017 — Accelerator Corporation a leading life science investment and management firm, today announced the appointments of Kendall Mohler, Ph.D., to the newly created position of chief development officer, and Ian Howes to chief financial officer. The firm also announced that it has changed its name to Accelerator Life Science Partners. The new name reflects Accelerator’s commitment to developing robust, long-term partnerships with its portfolio companies and to nurturing innovation and entrepreneurship within the life science community. This commitment is shared by Accelerator’s current investors, including AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., the Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund, WRF Capital, WuXi AppTec and 180 Degree Capital Corp.

“Innovation takes great ideas, and the translation of ideas into transformative life science products doesn’t occur in a vacuum,” said Thong Q. Le, chief executive officer at Accelerator. “We believe that fostering innovation requires more than providing capital and lab space. It also requires a shared passion for advancing human health and an understanding of how to navigate the complex landscape that such advances often require. The additions of Ken and Ian to our executive team enhances our ability to make that journey — for the benefit of our investors, our portfolio companies and the talented entrepreneurs we work with, and ultimately for patients in need.”

Dr. Mohler has more than two decades of experience in the biopharmaceutical industry, including several years leading scientific research and development teams in the areas of autoimmune disease, inflammation and oncology. He was chief scientific officer and, most recently, senior vice president of research at Juno Therapeutics, Inc. (NASDAQ: JUNO), a clinical-stage cell immunotherapy company focused on re-engaging the body’s immune system to treat cancer. Prior to Juno, Dr. Mohler co-founded Trubion Pharmaceuticals Inc., a biopharmaceutical company focused on the development of novel protein therapeutics to treat autoimmune and inflammatory diseases and cancer. While at Trubion, Dr. Mohler served as the company’s chief scientific officer and senior vice president, and oversaw the development of several first-in-class product candidates and supported several partnerships with global pharmaceutical companies. Dr. Mohler also previously served as vice president of biological sciences at Immunex Corporation, where he played critical roles in the development and approval of Enbrel (etanercept), a multi-billion dollar product for the treatment of several autoimmune diseases. Dr. Mohler has published more than 35 manuscripts and has four issued patents and six pending patent applications. He received a Ph.D. in Immunology from the University of Texas Health Science Center and a B.S. from the University of Kansas.

Mr. Howes has over 20 years of experience in senior financial roles developing early-stage life sciences companies, including the successful completion of numerous rounds of private and public equity and debt transactions and two initial public offerings. He also managed multiple M&A transactions, including the sale of Scioderm to Amicus Therapeutics and the sale of Serenex to Pfizer. Most recently, Mr. Howes served as CFO of Heart Metabolics, a venture-backed pharmaceutical company developing an innovative therapy for the treatment of hypertrophic cardiomyopathy. Previously, he was CFO of Scioderm, a pediatric orphan disease company; CFO for Akebia Therapeutics (NASDAQ: AKBA), a biotechnology company developing pharmaceutical drugs for anemia and ophthalmology; CFO and senior vice president of corporate development at Serenex, an integrated discovery and development oncology company; and CFO and vice president of operations at Paradigm Genetics (NASDAQ: PDGM). Mr. Howes began his professional career with Coopers & Lybrand in London. He is a Chartered Accountant and has an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.

About Accelerator Life Science Partners
Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations. Accelerator is a trusted partner that provides the complete business, scientific and financial toolkit necessary for successfully establishing and operating an early-stage biotechnology company. Accelerator nurtures its companies across all stages and in all facets of development, setting them on a path that offers the greatest chance for long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise and state-of-the-art laboratories and shared facilities.

The company is uniquely positioned to provide this unprecedented collection of capabilities and resources through its partnership with top-tier investors, seasoned executive managers and world-class research institutions. The value of these collective resources has been validated over more than a decade of successful investing in life science companies that are helping to shape the rapidly evolving future of medicine and healthcare. For more information, please visit www.acceleratorlsp.com.

 

Media Contacts:

Rathbun Communications
Julie Rathbun
julie@rathbuncomm.com

Accelerator Corporation
Jessica Burback
jburback@acceleratorcorp.com
T: 206-234-6481